PAR2通过干扰GLUT2和Akt促进NAFLD中的葡萄糖摄取受损和胰岛素抵抗
本研究探讨蛋白酶激活受体2(PAR2)是否将NAFLD/NASH与肝脏葡萄糖代谢联系起来。发现糖尿病和NAFLD/NASH患者及小鼠肝脏PAR2表达增加;PAR2通过Gq-MAPK-FoxA3下调GLUT2、通过Gq-钙-CaMKK2抑制胰岛素-Akt信号;肝脏归巢pepducin PZ-235阻断PAR2-Gq信号可改善严重糖尿病小鼠的血糖指标和HbA1c水平。
要点
- 糖尿病和NAFLD/NASH患者及小鼠肝脏PAR2表达增加。
- PAR2通过Gq-MAPK-FoxA3下调GLUT2,并通过Gq-钙-CaMKK2抑制胰岛素-Akt信号。
- PZ-235阻断PAR2-Gq信号可改善严重糖尿病小鼠的血糖指标和HbA1c水平。
核心结论
- PAR2是肝脏葡萄糖稳态的主要调节因子,也是治疗糖尿病和NASH的潜在靶点。
研究设计与样本
- 研究纳入糖尿病和NAFLD/NASH患者及小鼠,使用全身和肝脏特异性PAR2敲除小鼠进行机制研究,并以肝脏归巢pepducin PZ-235进行干预。
主要发现
- 糖尿病和NAFLD/NASH患者及小鼠肝脏PAR2表达增加。
- 全身和肝脏特异性PAR2敲除小鼠显示肝脏PAR2通过分支Gq依赖机制抑制葡萄糖内化、糖原储存和胰岛素信号。
- PAR2激活通过Gq-MAPK-FoxA3下调肝脏主要葡萄糖转运体GLUT2,并通过Gq-钙-CaMKK2抑制胰岛素-Akt信号。
- 肝脏归巢pepducin PZ-235阻断PAR2-Gq信号,使严重糖尿病小鼠的血糖指标和HbA1c水平获得显著改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Insulin resistance and poor glycemic control are key drivers of the development of NAFLD and have recently been shown to be associated with fibrosis progression in NASH. However, the underlying mechanisms involving dysfunctional glucose metabolism and relationship with NAFLD/NASH progression remain poorly understood. We set out to determine whether protease-activated receptor 2 (PAR2), a sensor of extracellular inflammatory and coagulation proteases, links NAFLD and NASH with liver glucose metabolism. APPROACH AND RESULTS: Here, we demonstrate that hepatic expression of PAR2 increases in patients and mice with diabetes and NAFLD/NASH. Mechanistic studies using whole-body and liver-specific PAR2-knockout mice reveal that hepatic PAR2 plays an unexpected role in suppressing glucose internalization, glycogen storage, and insulin signaling through a bifurcating Gq -dependent mechanism. PAR2 activation downregulates the major glucose transporter of liver, GLUT2, through Gq -MAPK-FoxA3 and inhibits insulin-Akt signaling through Gq -calcium-CaMKK2 pathways. Therapeutic dosing with a liver-homing pepducin, PZ-235, blocked PAR2-Gq signaling and afforded significant improvements in glycemic indices and HbA1c levels in severely diabetic mice. CONCLUSIONS: This work provides evidence that PAR2 is a major regulator of liver glucose homeostasis and a potential target for the treatment of diabetes and NASH.
引用
- Shearer AM, Wang Y, Fletcher EK, et al. PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference. Hepatology. 2022. PMID: 35603482. doi:10.1002/hep.32589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。